Cavernous Sinus Thrombosis Medication
- Author: Rahul Sharma, MD, MBA, FACEP; Chief Editor: Barry E Brenner, MD, PhD, FACEP more...
Antibiotic therapy ideally is started after appropriate cultures but should not be delayed if difficulties exist in obtaining specimens. Antibiotics selected should be broad-spectrum, particularly active against S aureus, and capable of achieving high levels in the cerebrospinal fluid. With the recent increased prevalence of community-acquired MRSA, the emergency physician should consider additional coverage with intravenous antibiotics, such as vancomycin, if MRSA infection is suspected.
However, a case report and literature review by Naesens et al of community-acquired MRSA infections of the central nervous system, including cavernous sinus thrombosis, showed that patients treated with linezolid had a better outcome than those treated with vancomycin.
Empiric broad-spectrum coverage for gram-positive, gram-negative, and anaerobic organisms is necessary. Therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.
In cases of suspected MRSA infection, vancomycin should be added for additional coverage.
A bactericidal antibiotic that inhibits cell wall synthesis. Used in treatment of infections caused by penicillinase-producing staphylococci. May be used to initiate therapy when staphylococcal infection is suspected.
Alternate antimicrobial choice. Third-generation cephalosporin that has broad gram-negative spectrum, lower efficacy against gram-positive organisms, and higher efficacy against resistant organisms than earlier generation cephalosporins. By binding to 1 or more penicillin-binding proteins, arrests bacterial cell wall synthesis and inhibits bacterial growth.
Additional anaerobic coverage. Imidazole ring-based antibiotic active against various anaerobic bacteria and protozoa. Usually employed in combination with other antimicrobial agents (except when used for Clostridium difficile enterocolitis, in which monotherapy appropriate).
Binds to 50S bacterial-ribosomal subunits and inhibits bacterial growth by inhibiting protein synthesis. Effective against gram-negative and gram-positive bacteria.
Indicated for patients who cannot receive or have failed to respond to penicillins and cephalosporins or have infections with resistant staphylococci. For abdominal penetrating injuries, it is combined with an agent active against enteric flora and/or anaerobes.
To avoid toxicity, current recommendation is to assay vancomycin trough levels after third dose drawn 0.5 h prior to next dosing. Use creatinine clearance to adjust dose in patients diagnosed with renal impairment.
Used in conjunction with gentamicin for prophylaxis in penicillin allergic patients undergoing gastrointestinal or genitourinary procedures.
Unfractionated IV heparin and fractionated low-molecular-weight SC heparins are the 2 options in anticoagulation therapy.
Augments activity of antithrombin III and prevents conversion of fibrinogen to fibrin. Does not actively lyse thrombus but able to inhibit further thrombogenesis. Prevents reaccumulation of clot after spontaneous fibrinolysis. Various dosing nomograms available.
These agents have anti-inflammatory properties and cause profound and varied metabolic effects. They modify the body's immune response to diverse stimuli. When the course of CST leads to pituitary insufficiency, corticosteroids definitely are indicated to prevent adrenal crisis.
DOC due to its mineralocorticoid activity and glucocorticoid effects. Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability. Useful in management of inflammation caused by an immune response.
Laupland KB. Vascular and parameningeal infections of the head and neck. Infect Dis Clin North Am. 2007 Jun. 21(2):577-90, viii. [Medline].
Seow VK, Chong CF, Wang TL, Lin CM, Lin IY. Cavernous sinus thrombophlebitis masquerading as ischaemic stroke: a catastrophic pitfall in any emergency department. Emerg Med J. 2007 Jun. 24(6):440. [Medline].
Duong DK, Leo MM, Mitchell EL. Neuro-ophthalmology. Emerg Med Clin North Am. 2008 Feb. 26(1):137-80, vii. [Medline].
Misra UK, Kalita J, Bansal V. D-dimer is useful in the diagnosis of cortical venous sinus thrombosis. Neurol India. 2009 Jan-Feb. 57(1):50-4. [Medline].
Pendharkar HS, Gupta AK, Bodhey N, Nair M. Diffusion restriction in thrombosed superior ophthalmic veins: two cases of diverse etiology and literature review. J Radiol Case Rep. 2011. 5(3):8-16. [Medline]. [Full Text].
Korchi AM, Cuvincius V, Caetano J, Becker M, Lovblad KO, Vargas MI. Imaging of the cavernous sinus lesions. Diagn Interv Imaging. 2014. 95(9):849-859.
Andrews CM, Hawk HE, Holmstedt CA. Case Report: Septic cavernous sinus thrombosis. Neurol Clin Neurosci. 2014. 2:117-118.
Tang Y, Booth T, Steward M, Solbach T, Wilhelm T. The imaging of conditions affecting the cavernous sinus. Clin Radiol. 2010 Nov. 65(11):937-45. [Medline].
Coutinho J, de Bruijn SF, Deveber G, Stam J. Anticoagulation for cerebral venous sinus thrombosis. Cochrane Database Syst Rev. 2011 Aug 10. CD002005. [Medline].
Coutinho JM, Ferro JM, Canhão P, Barinagarrementeria F, Bousser MG, Stam J. Unfractionated or low-molecular weight heparin for the treatment of cerebral venous thrombosis. Stroke. 2010 Nov. 41(11):2575-80. [Medline].
Naesens R, Ronsyn M, Druwé P, Denis O, Ieven M, Jeurissen A. Central nervous system invasion by community-acquired meticillin-resistant Staphylococcus aureus. J Med Microbiol. 2009 Sep. 58:1247-51. [Medline].
Bhatia K, Jones NS. Septic cavernous sinus thrombosis secondary to sinusitis: are anticoagulants indicated? A review of the literature. J Laryngol Otol. 2002 Sep. 116(9):667-76. [Medline].
Canhao P, Ferro JM, Lindgren AG. Causes and predictors of death in cerebral venous thrombosis. Stroke. 2005 Aug. 36(8):1720-5. [Medline].
Cannon ML, Antonio BL, McCloskey JJ, et al. Cavernous sinus thrombosis complicating sinusitis. Pediatr Crit Care Med. 2004 Jan. 5(1):86-8. [Medline].
DiNubile MJ. Septic thrombosis of the cavernous sinuses. Arch Neurol. 1988 May. 45(5):567-72. [Medline].
Ferro JM, Canhao P, Bousser MG. Cerebral vein and dural sinus thrombosis in elderly patients. Stroke. 2005 Sep. 36(9):1927-32. [Medline].
Goodwin WJ. Orbital complications of ethmoiditis. Otolaryngol Clin North Am. 1985 Feb. 18(1):139-47. [Medline].
Heckmann JG, Tomandl B. Cavernous sinus thrombosis. Lancet. 2003 Dec 13. 362(9400):1958. [Medline].
Karlin RJ, Robinson WA. Septic cavernous sinus thrombosis. Ann Emerg Med. 1984 Jun. 13(6):449-55. [Medline].
Lessner A, Stern GA. Preseptal and orbital cellulitis. Infect Dis Clin North Am. 1992 Dec. 6(4):933-52. [Medline].
Levine SR, Twyman RE, Gilman S. The role of anticoagulation in cavernous sinus thrombosis. Neurology. 1988 Apr. 38(4):517-22. [Medline].
Peters KS. Secondary headache and head pain emergencies. Prim Care. 2004 Jun. 31(2):381-93, vii. [Medline].
Schnipper D, Spiegel JH. Management of intracranial complications of sinus surgery. Otolaryngol Clin North Am. 2004 Apr. 37(2):453-72, ix. [Medline].
Southwick FS, Richardson EP, Swartz MN. Septic thrombosis of the dural venous sinuses. Medicine (Baltimore). 1986 Mar. 65(2):82-106. [Medline].
Watkins LM, Pasternack MS, Banks M. Bilateral cavernous sinus thromboses and intraorbital abscesses secondary to Streptococcus milleri. Ophthalmology. 2003 Mar. 110(3):569-74. [Medline].
Yanofsky NN. The acute painful eye. Emerg Med Clin North Am. 1988 Feb. 6(1):21-42. [Medline].
Zimmer J, Bhatt J, et al. Is it all in his head?. The Internet Journal of Pediatrics and Neonatology. 2006. 6: